Hypoglycemia - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Hypoglycemia - Pipeline Review, H1 2012', provides an overview of the Hypoglycemia therapeutic pipeline. This report provides information on the therapeutic development for Hypoglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoglycemia. 'Hypoglycemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Hypoglycemia.
- A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypoglycemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Hypoglycemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Hypoglycemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Hypoglycemia Overview
- Therapeutics Development
- An Overview of Pipeline Products for Hypoglycemia
- Hypoglycemia Therapeutics under Development by Companies
- Hypoglycemia Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Hypoglycemia Therapeutics - Products under Development by Companies
- Hypoglycemia Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Hypoglycemia Therapeutics Development
- Biodel Inc.
- Marcadia Biotech
- Hypoglycemia - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Byetta - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GLP-1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- insulin-like growth factor I - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allogeneic Islets Of Langerhans Transplant + Raptiva + Sirolimus + Anti-Thymocyte Globulin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MAR531 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BIOD-Stable Glucagon - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Hypoglycemia Therapeutics - Discontinued Products
- Hypoglycemia Therapeutics - Dormant Products
- Hypoglycemia - Product Development Milestones
- Featured News & Press Releases
- Jun 27, 2011: Novo Nordisk's Degludec Reduces Hypoglycaemia And Improves Long-Term Control In Patients With Type 1 And Type 2 Diabetes
- Jun 27, 2011: LCT Enrols First Patients In Phase II DIABECELL Argentina Trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Hypoglycemia, H1 2012
- Products under Development for Hypoglycemia - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Biodel Inc., H1 2012
- Marcadia Biotech, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Hypoglycemia Therapeutics - Discontinued Products
- Hypoglycemia Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Hypoglycemia, H1 2012
- Products under Development for Hypoglycemia - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
